Journal of Cardiac Failure最新文献

英文中文

NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial 高危心肌梗死后恢复期早期NT-proBNP与不良心血管结局相关：PARADISE-MI试验

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2025-04-16 DOI: 10.1016/j.cardfail.2025.03.018

KAROLA S. JERING MD , BRIAN L. CLAGGETT PhD , EUGENE BRAUNWALD MD , CHRISTOPHER B. GRANGER MD , LARS KØBER MD , ULF LANDMESSER MD , ELDRIN F. LEWIS MD, MPH , ALDO P. MAGGIONI MD , DOUGLAS L. MANN MD , JOHN JV MCMURRAY MD , ROXANA MEHRAN MD , MARK C. PETRIE MD , MARGARET F. PRESCOTT PhD , JEAN L. ROULEAU MD , MORTEN SCHOU MD , SCOTT D SOLOMON MD , PHILIPPE GABRIEL STEG MD , DIRK VON LEWINSKI MD , MARC A. PFEFFER MD, PhD

Background

N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with heart failure (HF) hospitalizations and death when measured during a myocardial infarction (MI). However, NT-proBNP concentrations change following the initial ischemic insult and less is known about the prognostic importance of NT-proBNP in the early convalescent phase.

Methods

PARADISE-MI randomized 5661 patients with MI complicated by LVEF ≤40% and/or pulmonary congestion to sacubitril/valsartan or ramipril. Patients with available week 2 NT-proBNP concentrations and without-incident HF between randomization and week 2 (n = 1062) were analyzed. Associations of week 2 NT-proBNP with subsequent clinical outcomes were evaluated in landmark analyses using Cox models adjusted for clinical characteristics, including LVEF, baseline NT-proBNP and atrial fibrillation.

Results

Median 2-week NT-proBNP concentration was 1391 [676–2507] ng/L. Patients in the highest NT-proBNP quartile (≥2507 ng/L) were older, had lower left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate (eGFR), higher Killip class, and more atrial fibrillation. Higher NT-proBNP concentrations were independently associated with greater risk of cardiovascular death or incident HF (adjusted hazard ratio [aHR], 1.65 per doubling of NT-proBNP; 95% confidence interval [CI], 1.31–2.09), HF hospitalization (aHR, 1.87; 95% CI, 1.38–2.54), recurrent myocardial infarction (aHR, 1.46; 95% CI, 1.09–1.95) and all-cause death (aHR, 1.85; 95% CI, 1.35–2.53).

Conclusions

Patients with elevated NT-proBNP concentrations approximately 2 weeks after a high-risk myocardial infarction are at heightened risk of incident HF, recurrent coronary events, and death independent of baseline NT-proBNP concentrations and clinical characteristics. Elevations in NT-proBNP concentrations in the early convalescent phase may assist in risk stratification and the identification of patients in need of more advanced preventive treatment approaches.

背景：在心肌梗死（MI）期间测量n端前b型利钠肽（NT-proBNP）与心力衰竭（HF）住院和死亡相关。然而，NT-proBNP浓度在初始缺血损伤后会发生变化，并且对于NT-proBNP在恢复期早期的预后重要性了解较少。方法：PARADISE-MI将5661例合并LVEF≤40%和/或肺充血的心肌梗死患者随机分配给苏比利/缬沙坦或雷米普利。在随机分组至第2周期间，具有第2周可用NT-proBNP浓度且未发生HF的患者（n=1062）进行了分析。在里程碑式分析中，使用校正LVEF、基线NT-proBNP和房颤等临床特征的Cox模型评估第2周NT-proBNP与随后临床结果的关联。结果：2周NT-proBNP中位数为1391 [676 - 2507]ng/L。NT-proBNP最高四分位数（≥2507 ng/L）的患者年龄较大，LVEF和eGFR较低，Killip分级较高，房颤发生率较高。较高的NT-proBNP浓度与CV死亡或心衰事件风险增加独立相关(NT-proBNP每增加一倍调整HR [aHR] 1.65；95% CI, 1.31-2.09)，心衰住院(aHR 1.87；95% CI, 1.38-2.54)，复发性心肌梗死(aHR 1.46；95% CI, 1.09-1.95)和全因死亡(aHR 1.85；95% ci, 1.35-2.53)。结论：高危心肌梗死后约两周NT-proBNP浓度升高的患者发生HF、冠状动脉事件复发和死亡的风险增加，与基线NT-proBNP浓度和临床特征无关。在恢复期早期NT-proBNP浓度的升高可能有助于风险分层和识别需要更先进的预防治疗方法的患者。摘要：n端前b型利钠肽（NT-proBNP）是心室壁应激的标志物，在心肌梗死（MI）急性期与不良心血管结局密切相关。NT-proBNP浓度在心肌梗死后发生动态变化，但在随访期间没有常规重新测量。在PARADISE-MI试验中招募的当代心肌梗死后人群中，心肌梗死后约两周测量的NT-proBNP与死亡、心力衰竭事件和心肌梗死复发的风险升高独立相关。早期恢复期的NT-proBNP浓度可能有助于心肌梗死患者的风险分层，并确定哪些患者需要更密切的随访和更积极的治疗。

{"title":"NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial","authors":"KAROLA S. JERING MD , BRIAN L. CLAGGETT PhD , EUGENE BRAUNWALD MD , CHRISTOPHER B. GRANGER MD , LARS KØBER MD , ULF LANDMESSER MD , ELDRIN F. LEWIS MD, MPH , ALDO P. MAGGIONI MD , DOUGLAS L. MANN MD , JOHN JV MCMURRAY MD , ROXANA MEHRAN MD , MARK C. PETRIE MD , MARGARET F. PRESCOTT PhD , JEAN L. ROULEAU MD , MORTEN SCHOU MD , SCOTT D SOLOMON MD , PHILIPPE GABRIEL STEG MD , DIRK VON LEWINSKI MD , MARC A. PFEFFER MD, PhD","doi":"10.1016/j.cardfail.2025.03.018","DOIUrl":"10.1016/j.cardfail.2025.03.018","url":null,"abstract":"<div><h3>Background</h3><div>N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with heart failure (HF) hospitalizations and death when measured during a myocardial infarction (MI). However, NT-proBNP concentrations change following the initial ischemic insult and less is known about the prognostic importance of NT-proBNP in the early convalescent phase.</div></div><div><h3>Methods</h3><div><span>PARADISE-MI randomized 5661 patients with MI complicated by LVEF ≤40% and/or </span>pulmonary congestion<span> to sacubitril/valsartan or ramipril<span><span>. Patients with available week 2 NT-proBNP concentrations and without-incident HF between randomization and week 2 (n = 1062) were analyzed. Associations of week 2 NT-proBNP with subsequent clinical outcomes were evaluated in landmark analyses using Cox models adjusted for clinical characteristics, including LVEF, baseline NT-proBNP and </span>atrial fibrillation.</span></span></div></div><div><h3>Results</h3><div>Median 2-week NT-proBNP concentration was 1391 [676–2507] ng/L. Patients in the highest NT-proBNP quartile (≥2507 ng/L) were older, had lower left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate<span> (eGFR), higher Killip class, and more atrial fibrillation. Higher NT-proBNP concentrations were independently associated with greater risk of cardiovascular death or incident HF (adjusted hazard ratio [aHR], 1.65 per doubling of NT-proBNP; 95% confidence interval [CI], 1.31–2.09), HF hospitalization (aHR, 1.87; 95% CI, 1.38–2.54), recurrent myocardial infarction (aHR, 1.46; 95% CI, 1.09–1.95) and all-cause death (aHR, 1.85; 95% CI, 1.35–2.53).</span></div></div><div><h3>Conclusions</h3><div>Patients with elevated NT-proBNP concentrations approximately 2 weeks after a high-risk myocardial infarction are at heightened risk of incident HF, recurrent coronary events, and death independent of baseline NT-proBNP concentrations and clinical characteristics. Elevations in NT-proBNP concentrations in the early convalescent phase may assist in risk stratification and the identification of patients in need of more advanced preventive treatment approaches.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 3","pages":"Pages 586-595"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Dietary Sodium Intake on Urinary Sodium Excretion in Healthy Volunteers 膳食钠摄入量对健康志愿者尿钠排泄的影响

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2025-10-10 DOI: 10.1016/j.cardfail.2025.09.033

EVELYNE MEEKERS MD , PIETER MARTENS MD, PhD, MSc , MARIE MISEUR , RUBEN KNEVELS , MARNICQ VAN ES MD , FREDERIK H. VERBRUGGE MD, PhD, MSc , PETRA NIJST MD, PhD , MATTHIAS DUPONT MD , WILFRIED MULLENS MD, PhD

引用次数: 0

Integrated Health Technologies in Heart Failure: A Scientific Statement From the Heart Failure Society of America and the American Association of Heart Failure Nurses 心力衰竭的综合健康技术：来自美国心力衰竭学会和美国心力衰竭护士协会的科学声明

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2026-01-27 DOI: 10.1016/j.cardfail.2025.08.029

MIA CAJITA PhD, RN , LAURA PETERS DNP, FNP , Vishal N. RAO MD, MPh , SPYROS KITSIOU PhD , JONATHAN W. LEIGH MPh, MShi , MAYANK M. KANSAL MD , KAREN M. VUCKOVIC PhD, APRN, ACNS-BC , CAROLYN MILLER REILLY PhD, RN, CNE, FAHA, FAAN , BIYKEM BOZKURT MD, PhD, FHFSA , SAVITRI FEDSON MD, MA , ADAM D. DEVORE MD, MHS

Integrated health technologies (IHTs) have emerged as promising tools for improving heart failure (HF) management by facilitating care coordination and enabling timely clinical intervention. This joint scientific statement from the Heart Failure Society of America and the American Association of Heart Failure Nurses summarizes current evidence about the use of IHTs in HF management, including traditional telemonitoring, mobile health-based remote monitoring, and implantable devices. IHT interventions have demonstrated benefits, such as improved quality of life and reduced hospitalization rates, but their effectiveness varies, depending on patients’ adherence, clinical integration, and feedback mechanisms. Challenges to widespread implementation of IHTs include suboptimal patient engagement, disparities in digital literacy and access, lack of interoperability between systems, concerns about data privacy and security, disruptions to clinician workflow, and substantial start-up and maintenance costs. This statement outlines strategies to overcome these challenges, including enhancing patients’ engagement through personalized, actionable feedback; improving digital literacy and access; advancing interoperability; ensuring data security; engaging clinicians during implementation to facilitate seamless integration; and expanding reimbursement. Finally, the statement proposes key priorities for future research, including the use of automation and machine learning to reduce clinician burden, the integration of emerging technologies that reduce patient burden, and the evaluation of cost-effectiveness to support broader implementation.

综合卫生技术（iht）通过促进护理协调和及时临床干预，已成为改善心力衰竭（HF）管理的有前途的工具。这份来自美国心力衰竭学会和美国心力衰竭护士协会的联合科学声明总结了目前在心力衰竭管理中使用iht的证据，包括传统的远程监测、基于健康的移动远程监测和植入式设备。IHT干预已显示出益处，如改善生活质量和降低住院率，但其有效性因患者的依从性、临床整合和反馈机制而异。广泛实施人工智能的挑战包括患者参与度不佳、数字素养和访问方面的差异、系统之间缺乏互操作性、对数据隐私和安全的担忧、对临床医生工作流程的干扰以及大量的启动和维护成本。本声明概述了克服这些挑战的策略，包括通过个性化的、可操作的反馈来提高患者的参与度；提高数字素养和获取；促进互操作性;确保数据安全；在实施过程中让临床医生参与，以促进无缝整合；扩大报销范围。最后，该声明提出了未来研究的关键优先事项，包括使用自动化和机器学习来减轻临床医生的负担，整合减轻患者负担的新兴技术，以及评估成本效益以支持更广泛的实施。

{"title":"Integrated Health Technologies in Heart Failure: A Scientific Statement From the Heart Failure Society of America and the American Association of Heart Failure Nurses","authors":"MIA CAJITA PhD, RN , LAURA PETERS DNP, FNP , Vishal N. RAO MD, MPh , SPYROS KITSIOU PhD , JONATHAN W. LEIGH MPh, MShi , MAYANK M. KANSAL MD , KAREN M. VUCKOVIC PhD, APRN, ACNS-BC , CAROLYN MILLER REILLY PhD, RN, CNE, FAHA, FAAN , BIYKEM BOZKURT MD, PhD, FHFSA , SAVITRI FEDSON MD, MA , ADAM D. DEVORE MD, MHS","doi":"10.1016/j.cardfail.2025.08.029","DOIUrl":"10.1016/j.cardfail.2025.08.029","url":null,"abstract":"<div><div>Integrated health technologies (IHTs) have emerged as promising tools for improving heart failure (HF) management by facilitating care coordination and enabling timely clinical intervention. This joint scientific statement from the Heart Failure Society of America and the American Association of Heart Failure Nurses summarizes current evidence about the use of IHTs in HF management, including traditional telemonitoring, mobile health-based remote monitoring, and implantable devices. IHT interventions have demonstrated benefits, such as improved quality of life and reduced hospitalization rates, but their effectiveness varies, depending on patients’ adherence, clinical integration, and feedback mechanisms. Challenges to widespread implementation of IHTs include suboptimal patient engagement, disparities in digital literacy and access, lack of interoperability between systems, concerns about data privacy and security, disruptions to clinician workflow, and substantial start-up and maintenance costs. This statement outlines strategies to overcome these challenges, including enhancing patients’ engagement through personalized, actionable feedback; improving digital literacy and access; advancing interoperability; ensuring data security; engaging clinicians during implementation to facilitate seamless integration; and expanding reimbursement. Finally, the statement proposes key priorities for future research, including the use of automation and machine learning to reduce clinician burden, the integration of emerging technologies that reduce patient burden, and the evaluation of cost-effectiveness to support broader implementation.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 3","pages":"Pages 619-632"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147419083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In Memoriam: Michael R. Bristow, MD, PhD 纪念：迈克尔R.布里斯托，医学博士，博士

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2026-02-10 DOI: 10.1016/j.cardfail.2026.01.003

MONA FIUZAT PHARMD , CHRISTOPHER M. O'CONNOR MD , DOUGLAS L. MANN MD

引用次数: 0

Predicted Heart Mass and Outcomes in the Contemporary Era of Heart Transplantation: Insights from the Dallas Heart Study 当代心脏移植时代预测的心脏质量和结果：来自达拉斯心脏研究的见解。

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2025-02-22 DOI: 10.1016/j.cardfail.2025.01.023

ERSILIA M. DEFILIPPIS MD , LAUREN K. TRUBY MD, MS , SONIA GARG MD , ELAINE WU , HADI BEAINI MD , MATTHIAS PELTZ MD , MARK H. DRAZNER MD, MSc , NATALIE BELLO MD , MARYJANE A. FARR MD, MSc

Background

Donor-recipient size matching is a key factor in donor selection for heart transplantation (HT). One approach uses predicted heart mass (PHM), derived from the Multi-Ethnic Study of Atherosclerosis (MESA). We sought to examine whether predicted left ventricular mass (PLVM) derived from the Dallas Heart Study (DHS) is associated with post-transplant outcomes.

Methods

The study cohort included participants without pre-existing cardiac disease in the DHS who had cardiac MRIs (n = 1746). A PLVM model was derived by linear regression. The DHS PLVM and MESA PHM were tested for correlation. The associations of the DHS PLVM and the MESA PHM with 1-year mortality post-HT were assessed in the United Network for Organ Sharing Registry in 3 eras: era 1: 1/1/2011–12/31/2014; era 2: 1/1/2015–10/17/2018; and era 3: 10/18/2018–12/31/2021). A pre-specified threshold for low donor-to-recipient mass ratio (< 0.86) was used in Kaplan-Meier survival estimation and univariate and multivariable Cox proportional hazard models.

Results

The DHS cohort had a median age of 43 (IQR 36–52) years, 49% male, 40% Black, and 18% Hispanic ethnicity. The DHS PLVM was highly correlated with the MESA PHM: r = 0.96; P < 0.001. In era 1, a low donor-to-recipient mass ratio according to the DHS PLVM was associated with increased 1-year mortality rates (log-rank P < 0.001) as was the MESA PHM (log rank P = 0.002). However, in eras 2 and 3, a low donor-to-recipient mass ratio by either the DHS PLVM or MESA PHM was not associated with increased 1-year mortality rates.

Conclusion

PLVM was highly correlated with PHM. A low donor-to-recipient mass ratio, whether assessed by PLVM or PHM, was associated with 1-year mortality post-HT in a historical era but not in the current era under the new allocation system. These findings suggest that other factors may be contributing to donor selection and mortality risk in the modern era.

背景：供体-受体大小匹配是心脏移植供体选择的关键因素。一种方法使用来自多种族动脉粥样硬化研究（MESA）的预测心脏质量（PHM）。我们试图检查来自达拉斯心脏研究（DHS）的预测左心室质量（PLVM）是否与移植后预后相关。方法：研究队列包括在DHS中没有既往心脏病且进行了心脏MRI检查的参与者（n=1,746）。通过线性回归建立了PLVM模型。DHS PLVM与MESA PHM进行相关性检验。DHS PLVM和MESA PHM与ht后1年死亡率的关系在器官共享登记联合网络（United Network for Organ Sharing Registry）中评估了三个时代（时代1:1/1/2011-12/31/2014，时代2:1/1/2015-10/17/2018和时代3:10/18/2018 - 12/31/2021）。Kaplan Meier生存估计和单变量和多变量Cox比例风险模型采用预先设定的低供体与受体质量比阈值（< 0.86）。结果：DHS队列的中位年龄为43岁（IQR 36-52岁），49%为男性，40%为黑人，18%为西班牙裔。DHS PLVM与MESA PHM高度相关：r = 0.96，p结论：PLVM与PHM高度相关。无论是通过PLVM还是PHM评估，较低的供体与受体质量比在历史时代与ht后1年死亡率相关，但在新的分配制度下，与当前时代无关。这些发现表明，在现代，其他因素也可能影响供体选择和死亡风险。

{"title":"Predicted Heart Mass and Outcomes in the Contemporary Era of Heart Transplantation: Insights from the Dallas Heart Study","authors":"ERSILIA M. DEFILIPPIS MD , LAUREN K. TRUBY MD, MS , SONIA GARG MD , ELAINE WU , HADI BEAINI MD , MATTHIAS PELTZ MD , MARK H. DRAZNER MD, MSc , NATALIE BELLO MD , MARYJANE A. FARR MD, MSc","doi":"10.1016/j.cardfail.2025.01.023","DOIUrl":"10.1016/j.cardfail.2025.01.023","url":null,"abstract":"<div><h3>Background</h3><div><span>Donor-recipient size matching is a key factor in donor selection for heart transplantation (HT). One approach uses predicted heart mass (PHM), derived from the Multi-Ethnic Study of </span>Atherosclerosis (MESA). We sought to examine whether predicted left ventricular mass (PLVM) derived from the Dallas Heart Study (DHS) is associated with post-transplant outcomes.</div></div><div><h3>Methods</h3><div><span><span>The study cohort included participants without pre-existing </span>cardiac disease in the DHS who had </span>cardiac MRIs<span> (n = 1746). A PLVM model was derived by linear regression<span>. The DHS PLVM and MESA PHM were tested for correlation. The associations of the DHS PLVM and the MESA PHM with 1-year mortality post-HT were assessed in the United Network for Organ Sharing Registry in 3 eras: era 1: 1/1/2011–12/31/2014; era 2: 1/1/2015–10/17/2018; and era 3: 10/18/2018–12/31/2021). A pre-specified threshold for low donor-to-recipient mass ratio (< 0.86) was used in Kaplan-Meier survival estimation and univariate and multivariable Cox proportional hazard models.</span></span></div></div><div><h3>Results</h3><div>The DHS cohort had a median age of 43 (IQR 36–52) years, 49% male, 40% Black, and 18% Hispanic ethnicity. The DHS PLVM was highly correlated with the MESA PHM: r = 0.96; <em>P</em><span> < 0.001. In era 1, a low donor-to-recipient mass ratio according to the DHS PLVM was associated with increased 1-year mortality rates (log-rank </span><em>P</em> < 0.001) as was the MESA PHM (log rank <em>P</em> = 0.002). However, in eras 2 and 3, a low donor-to-recipient mass ratio by either the DHS PLVM or MESA PHM was not associated with increased 1-year mortality rates.</div></div><div><h3>Conclusion</h3><div>PLVM was highly correlated with PHM. A low donor-to-recipient mass ratio, whether assessed by PLVM or PHM, was associated with 1-year mortality post-HT in a historical era but not in the current era under the new allocation system. These findings suggest that other factors may be contributing to donor selection and mortality risk in the modern era.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 3","pages":"Pages 608-615"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pocket Lung Ultrasound in Ambulatory Heart Failure With Preserved Ejection Fraction: Pulmonary Congestion as a Point-Of-Care Phenotype 袋肺超声在保留射血分数的动态心力衰竭：肺充血作为护理点表型。

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2026-02-07 DOI: 10.1016/j.cardfail.2026.02.004

SARA MOURA-FERREIRA MD , GIULIA CRISCI MD , JAN VERWERFT MD, PhD

引用次数: 0

HF Stats: Your Source for Citable, Shareable Heart Failure Data 心力衰竭统计：您可引用、可共享的心力衰竭数据来源

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2026-03-10 DOI: 10.1016/j.cardfail.2026.02.002

引用次数: 0

Sex Differences in N-Terminal Pro-B-Type Natriuretic Peptide Associations With Risk of Heart Failure Subtypes and Response to an Intensive Lifestyle Intervention in Type 2 Diabetes and Overweight or Obesity: a Post-hoc Analysis of the Look AHEAD (Action for Health in Diabetes) Trial 在2型糖尿病和超重或肥胖患者中，NT-proBNP的性别差异与心力衰竭亚型的风险和对强化生活方式干预的反应相关：Look AHEAD试验的事后分析：性别差异、NT-proBNP、T2D的HF亚型。

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2025-10-06 DOI: 10.1016/j.cardfail.2025.09.032

ZAINALI CHUNAWALA MD , KERSHAW V. PATEL MD, MSCS , KATELYN R. GARCIA MS , NEIL KESHVANI MD , MARK ESPELAND PhD , CHRISTIE M. BALLANTYNE MD , JAMES L. JANUZZI MD , CAROLYN S.P. LAM MBBS, PhD , ALAIN G. BERTONI MD, MPH , THOMAS J. WANG MD , ANTONI BAYES-GENIS MD, PhD , AMBARISH PANDEY MD, MSCS

引用次数: 0

Time-to-First Clinical Benefit of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure 胰高血糖素样肽-1受体激动剂治疗心力衰竭的首次临床获益时间。

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2025-11-20 DOI: 10.1016/j.cardfail.2025.11.489

CHRISTIAN BASILE MD , AURORA MEROLLA MD , COSTANTINO MANCUSI MD , PASQUALE AMBROSINO MD , REBECCA DE LORENZO MD , PATRIZIA ROVERE QUERINI MD , ALDO PIETRO MAGGIONI MD

引用次数: 0

Neutrophil Extracellular Traps in Heart Failure With Preserved Ejection Fraction: Linking inflammation to Cardiac Dysfunction HFpEF中的中性粒细胞胞外陷阱：炎症与心功能障碍的联系。

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure

Pub Date : 2026-03-01 Epub Date: 2026-01-14 DOI: 10.1016/j.cardfail.2026.01.001

VIRGINIA ANAGNOSTOPOULOU MD , CHRISTOFOROS K. TRAVLOS MD, MSc , ABHINAV SHARMA MD, PhD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Cardiac Failure

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀